RA'ANANA, Israel, April 16,
2024 /PRNewswire/ -- Inspira™ Technologies
OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the
"Company" or "Inspira"), a breakthrough medical technology
company, is proud to announce the signing of a collaboration term
sheet (the "Term Sheet") with the Beilinson Hospital in
Israel for the evaluation of its
proprietary INSPIRA ART100 device (the "Device") in organ
transplant procedures. This Term Sheet marks a significant
advancement and opportunity for the Company in its technology being
extended for use in additional medical segments and markets.
Under the evaluation agreement contemplated by the Term Sheet,
the hospital shall provide Inspira with access to the internally
logged data and diagnostics from the use of the Device and user
feedback from medical doctors, certified clinical perfusionists,
and other caregivers. The data is intended to be freely used by
Inspira.
Beilinson Hospital is the leading organ transplant center in
Israel, conducting over 70% of the
organ transplants in Israel. To
date, it has performed thousands of procedures, including more than
900 lung transplants. As a pioneering institution in kidney, lung,
heart, liver, and pancreas transplants, the Beilinson Hospital
oversees multiple organ donor programs and is involved in
international research studies.
The progression of the Term Sheet is subject to the subsequent
formalization of a detailed definitive evaluation agreement between
the parties.
Dr. Dan Gorfil, the head of the Cardiothoracic Surgery
Intensive Care Unit and the Extracorporeal Membrane Oxygenation
program at the Department of Cardiothoracic Surgery at Beilinson
Hospital, stated: "As physicians, our foremost commitment is to
our patients' well-being. Partnering with Inspira to assess the
INSPIRA ART100 device in organ transplant procedures aligns with
this commitment. This collaboration has the potential to enhance
patient outcomes, offering hope and possibility in the realm of
organ transplants."
The Term Sheet addresses the use of Inspira's proprietary
INSPIRA ART100 device in medical procedures in intensive care units
for life support and operating rooms to support organ transplants.
The primary objectives of the evaluation agreement are to assess
the functionality and performance of the Device in clinical
settings and healthcare delivery. The collaboration agreement is
conditional on regulatory clearance for the Device from the Israeli
Ministry of Health Medical Device Division.
Dagi Ben-Noon, CEO of Inspira, stated: "This Term
Sheet is a testament to our commitment to taking bold steps and
challenging the boundaries. Partnering with healthcare
professionals at Beilinson Hospital who are ready to embrace new
technologies marks a pivotal moment in our quest to redefine what
is possible in organ transplants and patient care."
About Beilinson Hospital
Beilinson Hospital is one of the most prominent and largest
medical facilities in Israel. Since its establishment almost
in 1936, Beilinson Hospital, led by Dr. Eytan Wirtheim, is a leader in developing and
implementing innovative treatments while maintaining the highest
standards of quality medical and care. Beilinson Hospital is a
leader in brain, heart and cancer treatment.
The 1,100-bed hospital, that serves the residents of
Central Israel, is staffed by a
team of 7,500 medical and support professionals, has 36 operations
rooms and performs 70% of all organs transplants in Israel. As a leader in kidney, lung, heart,
liver and pancreas transplants, Beilinson Hospital boasts an active
multiple organs and living-related donor program. The hospital
remains a pioneer in transplant procedures in the country.
About Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology
company in the respiratory treatment arena. The Company has
developed a breakthrough Augmented Respiration Technology (INSPIRA
ART), designed to rebalance patient oxygen saturation levels. This
technology potentially allows patients to remain awake during
treatment while reducing the need for highly invasive, risky, and
costly mechanical ventilation systems that require intubation and
medically induced coma. The Company's products have not yet been
tested or used in humans and has not been approved by any
regulatory entity.
For more information, please visit our corporate website:
https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the potential benefits
of the Company's products and potential products, that the
collaboration with Beilinson Hospital has the potential to enhance
patient outcomes, that the collaboration agreement is conditioned
on approval for the Device from the Israeli Ministry of Health
Medical Device Division and the signing of a definitive evaluation
agreement and that the evaluation agreement marks a pivotal moment
in the Company's quest to redefine what is possible in organ
transplants and patient care. These forward-looking statements and
their implications are based solely on the current expectations of
the Company's management and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as
otherwise required by law, the Company undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities
and Exchange Commission (the "SEC"), which is available on the
SEC's website, http://www.sec.gov.
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD. All
rights reserved.
Logo:
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
For more details:
Adi Shmueli
Public Relations Manager
Inspira Technologies
info@inspirao2.com
+972-9-9664485
View original
content:https://www.prnewswire.com/news-releases/inspira-signs-term-sheet-for-use-of-inspira-art100-device-in-organ-transplant-procedures-302118117.html
SOURCE Inspira Technologies